# Bifidobacterium adolescentis DSM 20083

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-adolescentis-dsm-20083
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** B. adolescentis DSM 20083, ATCC 15703, E194a variant, Bifidobacterium adolescentis ATCC 15703, DSM 20083 strain

## Overview

Bifidobacterium adolescentis DSM 20083 is a specific strain of gram-positive anaerobic bacteria classified under the Bifidobacterium genus, characterized by its bifid morphology and production of acetate and lactate via the fructose-6-phosphate phosphoketolase (F6PPK) pathway. No strain-specific clinical trials exist for DSM 20083, though the broader B. adolescentis species is studied for its capacity to ferment arabinoxylan, xylooligosaccharides (XOS), and galactooligosaccharides (GOS) into short-chain fatty acids.

## Health Benefits

• No clinical evidence available - species-level research suggests potential for short-chain fatty acid production, but strain-specific benefits unproven
• No clinical evidence available - general B. adolescentis strains studied for [prebiotic](/ingredients/condition/gut-health) [metabolism](/ingredients/condition/weight-management) (arabinoxylan, XOS, GOS), but no data for DSM 20083
• No clinical evidence available - species may contribute to GABA production, but strain-specific activity unconfirmed
• No clinical evidence available - potential B-vitamin synthesis (e.g., folic acid) noted at species level only
• No clinical evidence available - limited resistant starch degradation (2.8% ± 2.1%) observed in vitro only

## Mechanism of Action

B. adolescentis DSM 20083 metabolizes non-digestible dietary fibers through the fructose-6-phosphate phosphoketolase (F6PPK) pathway, yielding acetate, lactate, and formate as primary fermentation end-products. The strain expresses carbohydrate-active enzymes (CAZymes), including arabinofuranosidases and xylanases, enabling hydrolysis of arabinoxylan and xylooligosaccharides into fermentable monosaccharides. Resulting short-chain fatty acids, particularly acetate, may interact with colonic epithelial G-protein-coupled receptors GPR41 and GPR43, influencing [gut barrier](/ingredients/condition/gut-health) integrity and local immune signaling, though these effects are inferred from species-level data and not confirmed for DSM 20083 specifically.

## Clinical Summary

No published clinical trials have investigated Bifidobacterium adolescentis DSM 20083 as a standalone intervention in human subjects. At the species level, B. adolescentis strains have been evaluated in small in vitro fermentation studies and limited human [microbiome](/ingredients/condition/gut-health) research, primarily examining prebiotic substrate [metabolism](/ingredients/condition/weight-management) rather than measurable health endpoints. A 2012 study by Van den Abbeele et al. using a mucosal simulator of the human intestinal microbial ecosystem (M-SHIME) demonstrated B. adolescentis enrichment following arabinoxylan supplementation, but this was a model system with no direct clinical outcomes. Given the absence of randomized controlled trials, any health benefits attributed to DSM 20083 specifically remain speculative and unsupported by clinical evidence.

## Nutritional Profile

Bifidobacterium adolescentis DSM 20083 is a [probiotic](/ingredients/condition/gut-health) bacterial strain delivered in non-nutritive quantities (typically 1–10 billion CFU per serving), contributing negligible macronutrients (protein, fat, carbohydrates) or caloric value to the diet. The cells themselves contain bacterial structural components including peptidoglycan cell wall polymers, lipoteichoic acids, and exopolysaccharides. As a metabolically active fermentative organism, B. adolescentis species are known producers of short-chain fatty acids (SCFAs), primarily acetate and lactate as primary fermentation end-products, with minor formate production; butyrate production is minimal compared to species like B. longum. Species-level data indicates capacity for B-vitamin biosynthesis, particularly folate (vitamin B9) and riboflavin (vitamin B2), though strain-specific yields for DSM 20083 have not been quantified in published literature. The strain carries carbohydrate-active enzymes (CAZymes) enabling [metabolism](/ingredients/condition/weight-management) of arabinoxylan, xylo-oligosaccharides (XOS), and galacto-oligosaccharides (GOS), generating fermentation byproducts in situ. Species within B. adolescentis possess glutamate decarboxylase (GAD) enzyme activity associated with GABA biosynthesis from glutamate, but quantitative GABA output for DSM 20083 specifically is unreported. No direct mineral, fat-soluble vitamin, or fiber content is contributed by this ingredient at probiotic dosing levels.

## Dosage & Preparation

No clinically studied dosage ranges are available for Bifidobacterium adolescentis DSM 20083 in any form. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bifidobacterium adolescentis DSM 20083 has not been independently evaluated in formal human safety or tolerability trials, so a comprehensive safety profile specific to this strain does not exist. Bifidobacterium species broadly are classified as Generally Recognized As Safe (GRAS) by the FDA and carry Qualified Presumption of Safety (QPS) status from EFSA, suggesting a low inherent risk in healthy adults. Individuals who are immunocompromised, post-surgical, or have compromised gut mucosal integrity should exercise caution with any [probiotic](/ingredients/condition/gut-health) strain, as rare cases of bacteremia have been reported with Bifidobacterium spp. in vulnerable populations. No documented drug interactions or contraindications specific to DSM 20083 are established; concurrent antibiotic use may reduce viability of the strain if administered simultaneously.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses are available for Bifidobacterium adolescentis DSM 20083. The research consists solely of in-vitro characterization studies examining morphology and resistant starch degradation capabilities.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium adolescentis DSM 20083. It is a modern isolate from the pre-1990 era studied primarily in probiotic and [microbiome](/ingredients/condition/gut-health) research contexts.

## Synergistic Combinations

Other Bifidobacterium strains, [Prebiotic](/ingredients/condition/gut-health)s (XOS, GOS, arabinoxylan), Lactobacillus species, Dietary fiber

## Frequently Asked Questions

### What makes Bifidobacterium adolescentis DSM 20083 different from other B. adolescentis strains?

DSM 20083 is a deposited type strain held in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) culture collection, serving primarily as a reference strain for taxonomic and genomic studies rather than a commercially developed probiotic. While it shares the species-level traits of B. adolescentis—including arabinoxylan fermentation capacity and F6PPK pathway activity—no published research has characterized unique functional properties that distinguish DSM 20083 from other B. adolescentis isolates. Its primary scientific value lies in serving as a genomic and phenotypic benchmark for the species.

### Can Bifidobacterium adolescentis DSM 20083 produce short-chain fatty acids?

Based on species-level data, B. adolescentis strains including DSM 20083 are expected to produce acetate and lactate as primary fermentation products via the fructose-6-phosphate phosphoketolase pathway when supplied with fermentable substrates such as arabinoxylan, GOS, or XOS. Propionate and butyrate production is not characteristic of Bifidobacterium species directly, though acetate cross-feeding to butyrate-producing bacteria like Roseburia intestinalis has been described at the ecosystem level. Strain-specific short-chain fatty acid output data for DSM 20083 in human gut conditions has not been quantified in published literature.

### Is there any clinical evidence that Bifidobacterium adolescentis DSM 20083 improves gut health?

As of current published literature, there are no randomized controlled trials, cohort studies, or clinical pilot studies specifically investigating Bifidobacterium adolescentis DSM 20083 for gut health outcomes in humans. Evidence for B. adolescentis species more broadly is largely limited to in vitro fermentation models and observational microbiome studies, which cannot establish causation. Consumers should be aware that any health claims made for DSM 20083 supplements are not substantiated by strain-specific clinical trials.

### What prebiotics does Bifidobacterium adolescentis DSM 20083 ferment?

At the species level, B. adolescentis is documented to ferment arabinoxylan (AX), xylooligosaccharides (XOS), galactooligosaccharides (GOS), and fructooligosaccharides (FOS) through its carbohydrate-active enzyme repertoire, including arabinofuranosidases, beta-xylosidases, and beta-galactosidases. DSM 20083 as a type strain is expected to possess these metabolic capabilities, but substrate-specific fermentation efficiency data for this particular strain under physiological conditions has not been published. Pairing a B. adolescentis-containing probiotic with arabinoxylan or XOS prebiotics is theoretically synergistic based on species-level in vitro data.

### Is Bifidobacterium adolescentis DSM 20083 safe to take as a supplement?

Bifidobacterium adolescentis as a species carries GRAS status in the United States and QPS status from EFSA, indicating an established safety record in healthy adult populations. However, DSM 20083 specifically has not been evaluated in dedicated human safety trials, so tolerability data such as rates of bloating, gas, or adverse events for this strain are unavailable. Immunocompromised individuals, those with central venous catheters, or patients recovering from gastrointestinal surgery should consult a physician before taking any probiotic, as rare opportunistic infections with Bifidobacterium spp. have been documented in high-risk clinical settings.

### How long does it typically take for Bifidobacterium adolescentis DSM 20083 to colonize the gut?

Most probiotic strains, including Bifidobacterium species, require consistent daily supplementation for 2-4 weeks to establish measurable presence in the gut microbiome. However, colonization duration varies significantly between individuals based on existing microbiota composition, diet, and antibiotic use. DSM 20083 specific colonization timelines have not been formally documented in clinical studies.

### Is Bifidobacterium adolescentis DSM 20083 suitable for people taking antibiotics?

Probiotics are commonly taken during and after antibiotic courses to help restore beneficial bacteria, though they should ideally be taken 2-3 hours apart from antibiotics to avoid direct contact. Bifidobacterium adolescentis DSM 20083 has not been specifically studied for antibiotic resilience or optimal timing in clinical populations. Consult a healthcare provider about spacing and continued use during antibiotic treatment.

### What shelf-life and storage conditions does Bifidobacterium adolescentis DSM 20083 require?

Bifidobacterium strains are sensitive to heat, moisture, and oxygen, typically requiring refrigeration (2-8°C) or freeze-dried formulations to maintain viability during storage. Product-specific stability data for DSM 20083 depends on the supplement manufacturer's formulation and packaging technology. Check the supplement label for manufacturer-recommended storage conditions and expiration date to ensure potency.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*